Pembrolizumab demonstrated durable anti-tumor activity in various tumors specially Hodgkin Lymphoma (ORR: 50%, mPFS: 12.2 months, 12 month PFS rate: 59.7%). The results indicate further study of pembrolizumab in pediatric patients with particulate interest in Lymphoma Phase 2 Study results confirms PR rate of 72% with that of phase 1 (71%). Most responses were sustained ≥6 months. Improvements in PN related pain and motor impairment demonstrate that selumetinib can provide clinical benefit Trametinib demonstrated ORR
Why is it so difficult to develop drugs for children with cancer? What can be done to stimlate investments in the pediatric oncology space? These questions are central to a new study published by MIT Sloan researchers that explores new business models for funding drug development to treat pediatric cancers. The presentation sumamrizes the key findings of the study & talks about the challenges of developing drugs for pediatric cancer–and offers a potential solution. The study
Research and development within the cancer field is continuously evolving and progressing. This video highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.
Abstract 7504: Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 (5F9) with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Conclusion: 5F9 + rituximab is a novel immunotherapy that inhibits a key macrophage/cancer checkpoint. It is well tolerated with no MTD reached and has promising clinical activity in rituximab-refractory DLBCL and FL patients including multiple CRs. Phase 2 cohorts are ongoing in indolent lymphoma and DLBCL The U.S. FDA has granted fast
Abstract 5003: Olaparib (Lynparza) combined with abiraterone (Zytiga) in patients with metastatic castration-resistant prostate cancer (mCRPC): a randomized phase II trial Conclusion: This is the first trial to show clinical benefit (increase in PFS) for mCRPC pts treated with a PARP inhibitor combined with abiraterone, regardless of HRRm status. Safety data were less favorable for the combination, but no detriment to QoL was seen. The study indicates synergy between olaparib and abiraterone. Abstract 5004: The
Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the similar outcomes as it does for patients with HER2-positive breast cancer. This is a very important study given that continuation of trastuzumab beyond progression in